UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 745

Sortiert nach

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Cancer chemotherapy and pharmacology, 2013-04, Vol.71 (4), p.829-842

Burris, Howard A.

2013

Volltextzugriff (PDF)

Revolutionizing cancer drug development: Harnessing the potential of basket trials

Cancer, 2024-01, Vol.130 (2), p.186-200

2024

Volltextzugriff (PDF)

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Journal of clinical oncology, 2011-02, Vol.29 (4), p.398-405

2011

Volltextzugriff (PDF)

2020 ASCO Presidential Address: Unite and Conquer-Accelerating Progress Together

Journal of clinical oncology, 2020-08, Vol.38 (24), p.2703-2705

Burris, 3rd, Howard A Skip

2020

Volltextzugriff (PDF)

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Clinical cancer research, 2021-08, Vol.27 (16), p.4491-4499

2021

Volltextzugriff (PDF)

The National Clinical Trials Network: A Valuable and Undervalued Resource

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1976-1978

Burris, 3rd, Howard A

2023

Volltextzugriff (PDF)

Correcting the ASCO position on phase I clinical trials in cancer

Nature reviews. Clinical oncology, 2020-02, Vol.17 (2), p.125-125

Burris, 3rd, Howard A

2020

Volltextzugriff (PDF)

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19

The Journal of clinical investigation, 2021-10, Vol.131 (20), p.1-13

2021

Volltextzugriff (PDF)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

2012

Volltextzugriff (PDF)

Radiation Recall with Anticancer Agents

The oncologist (Dayton, Ohio), 2010-11, Vol.15 (11), p.1227-1237

2010

Volltextzugriff (PDF)

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2012-01, Vol.30 (3), p.282-290

2012

Volltextzugriff (PDF)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

The oncologist (Dayton, Ohio), 2023-07, Vol.28 (7), p.640-e559

2023

Volltextzugriff (PDF)

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Breast cancer research and treatment, 2015-11, Vol.154 (1), p.89-97

2015

Volltextzugriff (PDF)

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Clinical cancer research, 2012-09, Vol.18 (17), p.4775-4784

2012

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1588-1595

2008

Volltextzugriff (PDF)

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2311-2319

2008

Volltextzugriff (PDF)

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3230-3237

2007

Volltextzugriff (PDF)

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

The lancet oncology, 2018-04, Vol.19 (4), p.486-496

2018

Volltextzugriff (PDF)

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

The New England journal of medicine, 2012-11, Vol.367 (18), p.1694-1703

2012

Volltextzugriff (PDF)

Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab

Journal of clinical oncology, 2010-01, Vol.28 (1), p.43-48

2010

Volltextzugriff (PDF)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC cancer, 2019-05, Vol.19 (1), p.517-517, Article 517

2019

Volltextzugriff (PDF)

1 – 25 von 745

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(732)
Mit Volltextzugriff
(702)

Publikationsform

Sprache

Englisch
(745)
Japanisch
(44)

Erscheinungsjahr

n.n

Thema

Science & Technology
(345)
Life Sciences & Biomedicine
(344)
Humans
(338)
Oncology
(314)
Female
(283)
Middle Aged
(259)
Aged
(250)
Adult
(228)
Male
(219)
Biological And Medical Sciences
(138)
Medical Sciences
(137)
Aged, 80 And Over
(134)
Treatment Outcome
(119)
Tumors
(119)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(108)
Neoplasms - Drug Therapy
(107)
Pharmacology. Drug Treatments
(90)
Antineoplastic Agents
(88)
Chemotherapy
(82)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(79)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(247)
Cancer Research
(60)
Cancer
(38)
Clinical Cancer Research
(34)
Cancer Chemotherapy And Pharmacology
(22)
Molecular Cancer Therapeutics
(21)
Investigational New Drugs
(18)
The Oncologist
(18)
Blood
(17)
The oncologist
(17)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Revolutionizing cancer drug development: Harnessing the potential of basket trials

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2020 ASCO Presidential Address: Unite and Conquer-Accelerating Progress Together

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

The National Clinical Trials Network: A Valuable and Undervalued Resource

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Correcting the ASCO position on phase I clinical trials in cancer

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Radiation Recall with Anticancer Agents

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Suchergebnisse filtern